Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $410M | $434M | $453M | $460M | $407M | $464M | $461M | $747M | $799M | $822M |
| Revenue growth | — | 5.9% | 4.4% | 1.5% | -11.6% | 14.2% | -0.8% | 62.1% | 7.1% | 2.9% |
| Gross profit | $322M | $341M | $356M | $359M | $305M | $350M | $337M | $486M | $546M | $566M |
| Gross margin | 78.6% | 78.6% | 78.7% | 78.1% | 74.9% | 75.3% | 73.2% | 65.1% | 68.3% | 68.8% |
| Operating income | $21.1M | $40.8M | $30.1M | -$18.8M | -$6.27M | -$8.31M | -$13.3M | -$139M | -$84.6M | -$81.4M |
| Operating margin | 5.1% | 9.4% | 6.6% | -4.1% | -1.5% | -1.8% | -2.9% | -18.6% | -10.6% | -9.9% |
| Net income | $3.06M | $6.22M | $13.8M | -$28.5M | $2.52M | -$38.4M | -$19.7M | -$151M | -$126M | -$92.2M |
| Net margin | 0.7% | 1.4% | 3.0% | -6.2% | 0.6% | -8.3% | -4.3% | -20.3% | -15.8% | -11.2% |
| EPS (diluted) | $0.17 | $0.34 | $0.72 | -$1.51 | $0.13 | -$1.95 | -$0.98 | -$4.12 | -$3.30 | -$2.33 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $59.1M | $39.0M | $49.9M | $32.0M | $74.3M | $18.5M | -$11.5M | -$45.8M | $25.8M | $33.3M |
| Capital expenditures | $16.4M | $14.7M | $13.6M | $19.0M | $15.5M | $17.8M | $23.2M | $62.0M | $34.9M | $34.6M |
| Free cash flow | $42.6M | $24.3M | $36.3M | $13.0M | $58.8M | $690K | -$34.7M | -$108M | -$9.09M | -$1.28M |
| Share buybacks | $63.4M | — | — | — | — | — | — | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $39.6M | $81.2M | $69.6M | $69.7M | $96.3M | $87.8M | $50.7M | $33.1M | $83.2M | $82.0M |
| Total assets | $372M | $405M | $467M | $496M | $526M | $477M | $459M | $925M | $893M | $851M |
| Total liabilities | $109M | $109M | $131M | $168M | $169M | $140M | $122M | $327M | $390M | $401M |
| Long-term debt | — | — | — | — | — | — | — | $93.1M | $157M | $157M |
| Shareholders' equity | $263M | $297M | $335M | $328M | $357M | $337M | $337M | $599M | $503M | $450M |
| Retained earnings | $64.2M | $70.4M | $87.1M | $57.7M | $59.4M | $21.0M | $1.25M | -$150M | -$276M | -$368M |
| Shares (wtd avg diluted) | 18.5M | 18.5M | 18.9M | 18.9M | 19.4M | 19.7M | 20.1M | 36.7M | 38.1M | 39.6M |
Every figure is extracted from Orthofix Medical Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.